Zhao et al. (2017) used CD5-2 to inhibit vascular endothelial-cadherin (VE-cadherin) in tumor-related blood vessels and observed an increase in CD8+ T cells infiltrating and cytotoxicity, which gave another idea of using T-cell infiltrating in tumor immunotherapy. The gene discussed is CD52; the disease is neoplasm.